Penumbra presented STORM-PE data while Penumbra stock trades at EUR 281.30

Published on 10/08/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Penumbra stock costs EUR 281.30 on October 8, 2026 after EUR 282.60. Second-quarter revenue reached USD 390.05 million, up 14.90 percent year over year.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra (US70975L1070) was trading at EUR 281.30 at Lang & Schwarz on October 8, 2026 at 11:09 a.m. CEST, while Penumbra had presented STORM-PE findings on October 6, 2026, according to PR Newswire. The euro quote was down 0.46 percent versus the EUR 282.60 prior close at Lang & Schwarz.

STORM-PE links activity and recovery

PR Newswire reported on October 6, 2026 that Penumbra's subset analysis linked daily step counts, walking-bout measures and peak 10-minute step counts with performance on a 6-minute walk test after 30 days. The correlations were weaker at the 90-day follow-up, giving the data a clear time dimension rather than a single endpoint.

The STORM-PE randomized trial enrolled 100 patients across 22 international sites and compared computer-assisted vacuum thrombectomy plus anticoagulation with anticoagulation alone. The company also presented interim results from 1,000 prospective STRIKE-PE patients, although the release said STORM-PE was not powered to detect differences in safety.

Revenue growth contrasts with earnings miss

Penumbra's second-quarter 2026 revenue was USD 390.05 million, up 14.90 percent from the prior-year quarter, while GAAP earnings per share were USD 0.88 against a USD 1.16 consensus estimate, according to MarketBeat. Revenue therefore exceeded the USD 389.64 million estimate, but earnings missed by USD 0.28 per share.

The contrast matters for the stock: operating growth remains visible, yet the earnings shortfall places greater weight on product adoption and execution. Penumbra's investor-relations materials describe a medical-device portfolio serving hospitals and clinics in more than 100 countries, with thrombectomy products central to its business.

Stock stays below its yearly high

Penumbra stock had a market capitalization of USD 12.5 billion as of October 7, 2026. Its primary-exchange 52-week range was USD 221.26 to USD 362.41 on that date, leaving the current USD market context below the yearly high while the reference quote remains in euros.

Price points to a cautious session

At Lang & Schwarz, Penumbra was trading at EUR 281.30 on October 8, 2026 at 11:09 a.m. CEST, down 0.46 percent from the EUR 282.60 prior close dated October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Penumbra stock.